Using data from a large collaboration of 22 studies in Europe, Australia, and Canada (CASCADE), Kholoud Porter from the UK Medical Research Council Clinical Trials Unit and colleagues assessed the continuing effect of HAART on survival and progression to AIDS after HIV-1 seroconversion (the point at which antibodies to HIV-1 infection are detectable in blood). The investigators compared the effects of age at seroconversion, exposure category, sex, and presentation during acute HIV-1 infection pre-1997 (pre-HAART), in 1997-98 (limited use of HAART), and 1999-2001 (widespread use of HAART).
Compared with pre-1997 data, death rates were reduced by 50% in 1997, and by over 80% by 2001; during this time use of HAART therapy increased from 22% in 1997 to 57% in 2001. The largest reduction in mortality occured soon after HAART first became available in 1997.
By contrast with the pre-HAART era, injecting drug users had death rates four times greater in 1999-2001 than men infected through homosexual contact. Whereas pre-1997 the risk of AIDS was higher in those aged 45 years or older at seroconversion than in people who were 16-24 years, there was little evidence of a difference in risk by age in 1999-2001.
Kholoud Porter comments: "Now that HAART therapy is available, 9 out of 10 people infected with HIV-1 can expect to survive more than 10 years, regardless of their age. Earlier diagnosis provides opportunities t
'"/>
Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
16-Oct-2003